This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

8 Jul 2011

Evotec and UCB Ink Neurological Discovery Pact

Evotec and UCB have agreed to jointly identify small modulators of priority biological targets for CNS disorders.

Evotec AG announced yesterday it has signed a drug discovery collaboration agreement with UCB to identify small molecule modulators of biological targets selected by UCB, in central nervous system disorders.


According to the three-year deal, Evotec will apply its integrated drug discovery expertise and technologies to identify small molecules against the selected targets to be further optimized through lead optimization to a preclinical candidate. Evotec will receive fixed research funding and early stage discovery, preclinical and clinical milestones as well as royalties on sales of any approved drugs from the collaboration.


Dr. Mario Polywka, Evotec’s chief operating officer, said, “We are extremely pleased that UCB selected Evotec to collaborate on

Related News